

# Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

NCT06705686

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	TechnoGenesys, Inc.
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (25)

- Histologically or cytologically confirmed prostate cancer (mCRPC).
- Must have evidence of metastatic disease on conventional imaging (eg. CT, MRI, technetium bone scan). May have any type or location of metastases (bone, lymph node, visceral). RECIST 1.1 measurable disease is not required; may have bone-only metastases.
- Ongoing androgen deprivation therapy (ADT) at time of study enrollment (GnRHR agonist such as leuprolide, goserelin, triptorelin, buserelin, histrelin; GnRHR antagonists such as degarelix or relugolix), or history of surgical castration.
- Must have evidence of castrate testosterone levels with baseline serum testosterone level of 50 ng/dL or less at time of study start, and castrate levels should be maintained throughout study.
- Evidence of progressive castration-resistant prostate cancer, defined as at least 2 consecutive rises of PSA, at least 1 week apart with the last PSA  $\geq 2$  ng/mL or by evidence of radiographic progression.

... and 20 more (see full listing online)

### Exclusion (39)

- Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 14 days before first dose of study treatment.
- Exclusively small cell variant of prostate cancer, or other prostate cancer histology that does not contain adenocarcinoma
- Inability to swallow pills.
- Presence of a condition requiring systemic treatment with either corticosteroids ( $> 10$  mg daily prednisone equivalent) or other immunosuppressive medications within 14 calendar days of start of study treatment. Inhaled or topical steroids and adrenal replacement steroid doses  $< 10$  mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
- Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, or superficial bladder cancer. Any history of prior malignancy must be reviewed by the PI.

... and 34 more (see full listing online)

## Locations (1 total)

---

University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect, Madison, Wisconsin, United States

---

<https://clinicaltrials.gov/study/NCT06705686>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).